Source: HeraMed
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Maternity care company HeraMED’s (HMD) digital monitoring technology, HeraCare, has been shortlisted for a Government tender in Spain
  • The tender is part of a comprehensive technology solution for obstetrics departments in nine hospitals in Catalonia
  • HeraMED and distributors Hospital Hispania have signed a memorandum of understanding (MOU)
  • Under the MOU Hospital Hispania will promote and market the HeraCARE technology in the Spanish market
  • HeraMED is trading 2.78 per cent up at 18.5 cents per share at 1:48 pm AEST

HeraMED’s (HMD) technology solution, HeraCare, has been shortlisted for a Government tender in Spain.

HeraCare is a digital pregnancy monitoring platform aiming to improve prenatal and postnatal care.

The tender is part of a comprehensive technology solution for obstetrics departments in nine hospitals in Catalonia, led by Hospital Hispania.

Hospital Hispania has more than 25 years of experience and a national distribution network across Spain, offering innovative medical technologies and equipment.

The parties have signed a memorandum of understanding, which will see Hospital Hispania promote and market the HeraCARE technology in the Spanish market.

Under the agreement, Hospital Hispania has agreed to purchase a number of HeraBEAT and HeraCare software platform licences for about US$250,000 (around A$341,000) in 2022.

HeraMED CEO and co-founder, David Groberman, is pleased to sign with Hospital Hispania.

“We are encouraged by the significant interest taken by the team at Hospital Hispania to collaborate with HeraMED, and for their plans to promote the technology across their network of hospitals and medical practitioners in Spain,” he said.

HeraMED was trading 2.78 per cent up at 18.5 cents per share at 1:48 pm AEST.

HMD by the numbers
More From The Market Herald

" Resonance Health (ASX:RHT) contracted for third party liver disease study

Resonance Health (ASX:RHT) has been contracted to provide liver-fat quantification services for a clinical study to…

" Cann Group (ASX:CAN) granted GMP licence by TGA

Cann Group (ASX:CAN) receives a GMP licence from the Therapeutic Goods Administration (TGA) to manufacture therapeutic…
1st Group (ASX:1ST) - Managing Director, Klaus Bartosch

" 1st Group (ASX:1ST) shares rise on Visionflex acquisition

Digital health company 1st Group (ASX:1ST) was up as much as 25 per cent on the…
Atomo Diagnostics (ASX:AT1) - Managing Director, John Kelly

" Atomo Diagnostics (ASX:AT1) sees growth in cash receipts as demand for rapid antigen tests soars

Atomo Diagnostics (ASX:AT1) sees growth in cash receipts as demand for rapid antigen tests soars